TO ASSESS REDUCTION IN MACULAR EDEMA BY SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY (SD-OCT) FOLLOWING INJECTION OF BEVACIZUMAB IN CASES OF CENTRAL RETINAL VEIN OCCLUSION (CRVO)

Aim: To study the reduction in macular oedema in Central Retinal Vein Occlusion cases following Intravitreal injection of Bevacizumab using Spectral Domain Optical Coherence Tomography. Methods: 50 patients diagnosed with Central Retinal Vein Occlusion with macular oedema of more than 300 microns on Spectral Domain Optical Coherence Tomography ( SD-OCT) ,who attended to Out patient Department of Government Regional Eye Hospital (GREH) between January 2020 to June 2020 were administered Intravitreal Injection of Bevacizumab (Avastin) 1.25mg in 0.05ml. Re-injections were given if SD-OCT showed persistence of macular oedema. In follow up visits, patients were evaluated with SD-OCT and Central macular thickness (CMT) was measured every month till 6 months from the date of first injection. Results: Out of 50 cases included in the study, there was reduction in macular oedema in 45 (90%) cases and 5% had persistence of macular edema. Conclusion: Intravitreal Bevacizumab is a safe and effective modality of treatment for reducing macular edema due to Central Retinal Vein Occlusion as per our study.